Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer
In This Article:
Pfizer (PFE) and Astellas Pharma said additional follow-up results from a phase 3 clinical trial of
Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.
Terms and Privacy Policy